A Randomized Controlled Trial of Immersive Virtual Reality in Interventional Radiology: IRVARI study
Radiology Advances · 20.11.2026
DOI: 10.1093/radadv/umag048 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Radiology Advances, online erschienen am 20.11.2026. Verfasst von Audrey Fohlen und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Most interventional radiology (IR) procedures can be a source of anxiety and pain for patients. A virtual reality (VR) device may facilitate relaxation and pain alleviation.
Purpose
To evaluate the effect of a VR headset during IR procedures in reducing patient pain and anxiety. Materials and Methods In this prospective, randomized, single-center study (IRVARI), from June 2021 to June 2023, adult patients planned for liver biopsy, trans-arterial chemoembolization, varicocele, pelvic vein or uterine fibroid embolization were enrolled. Two groups were defined: VR-based conditions vs. standard care control. Intervention-induced anxiety was evaluated by the State-Trait Anxiety Inventory in its State Anxiety component (STAI-YA). Anxiety and pain were measured at different times with a numeric rating scale (NRS). Hemodynamic parameters, use of analgesic and anxiolytic medication and procedural time were recorded. Adverse effects and patient satisfaction with the VR headset were documented. For STAI-YA, mean results were compared using Cohen’s d random-effects method, and p-values were calculated with ANOVA and Mann-Whitney tests.
Results
143 patients (mean age, 54 years ± 18 [standard deviation]; 101 men) were analyzed, 72 in the VR group. The VR group had a lower mean score for anxiety (STAI-YA) of 21.2% (p < 0.001) with an important effect size (Cohen’s d = 0.717). Post-intervention anxiety and pain levels were significantly lower (p = 0.001) in the VR group. Systolic arterial blood pressure was significantly lower (p = 0.038) in the VR group regardless of the time point. No difference in analgesic, anxiolytic use and procedural time was noted between the groups. An adverse effect related to the VR headset (i.e. discomfort) was reported in 1.4% (1/72); 88.9% (64/72) were satisfied with the VR device.
Conclusion
Use of VR is an effective and feasible nonpharmacologic adjunct for reducing anxiety and pain during IR procedures. Its integration into clinical practice may improve patient experience without increasing procedural burden.
Zitieren
APA
Fohlen, A., Garreau, H., Bolnavu, I., Morello, R., & Pelage, J. P. (2026). A Randomized Controlled Trial of Immersive Virtual Reality in Interventional Radiology: IRVARI study. Radiology Advances. https://doi.org/10.1093/radadv/umag048
Vancouver
Fohlen A, Garreau H, Bolnavu I, Morello R, Pelage JP. A Randomized Controlled Trial of Immersive Virtual Reality in Interventional Radiology: IRVARI study. Radiology Advances. 2026. doi:10.1093/radadv/umag048
BibTeX
@article{Fohlen2026,
author = {Fohlen, Audrey and Garreau, Henri and Bolnavu, Iulia and Morello, Remy and Pelage, Jean Pierre},
title = {A Randomized Controlled Trial of Immersive Virtual Reality in Interventional Radiology: IRVARI study},
journal = {Radiology Advances},
year = {2026},
doi = {10.1093/radadv/umag048}
}
EUVIMED